1. Generics Bulletin
  2. >>Products

Coherus And AbbVie Trade Legal Blows Amid Radical Adalimumab Price Offering

PBM SmithRx Works With Mark Cuban’s Firm To Offer Biosimilar At More Than 90% Off

 
• By Dean Rudge

Coherus BioSciences’ plans earlier this month to launch its Humira biosimilar, Yusimry, at a massive discount have sparked both a legal battle and an arrangement with a “next generation” pharmacy benefit manager.

Breach of contract
• Source: Shutterstock

Just weeks before its Yusimry (adalimumab-aqvh) biosimilar to AbbVie’s Humira is set to reach the US market, Coherus BioSciences’ radical plan to offer “the lowest price announced to date of any adalimumab offering in the US” – a mammoth 85% discount to Humira’s $6,922 current list price for a carton of two autoinjectors – has sparked a legal dispute between the companies, albeit one which appears to have cooled as the biosimilar’s launch date approaches.

At the beginning of June, Coherus announced that it had joined forces with Cost Plus Drugs to offer upon Yusimry’s proposed launch on 1 July the biosimilar at a more than 90% discount to

More from Biosimilars

More from Products

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.